Literature DB >> 15054824

Prompt response to rituximab of severe hemolytic anemia with both cold and warm autoantibodies.

Duncan Webster1, Bruce Ritchie, Michael J Mant.   

Abstract

A 71-year-old male with severe autoimmune hemolysis with both cold agglutinins and warm antibodies was intolerant of prednisone and cyclophosphamide. Rituximab was given during a 60-day period when he required 41 units of packed cells to maintain hemoglobin above 75 g/l. Two weeks later hemoglobin stabilized at 95 g/l, and further transfusions were not required. A second course of rituximab was given 4 months later for continued hemolysis. A satisfactory hemoglobin was maintained for 9 months from initial treatment, when hemoglobin again fell to 65 g/L. A prompt response to a third course of rituximab was obtained. This is the second patient with both cold agglutinins and warm antibodies with severe hemolytic anemia who has had a prompt response to rituximab. This treatment should be considered when a rapid response is needed or when a patient has failed to respond to more standard therapies. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15054824     DOI: 10.1002/ajh.20034

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  A patient with mixed type Evans syndrome: efficacy of rituximab treatment.

Authors:  Chi Young Park; Choon Hae Chung
Journal:  J Korean Med Sci       Date:  2006-12       Impact factor: 2.153

2.  Severe refractory autoimmune hemolytic anemia with both warm and cold autoantibodies that responded completely to a single cycle of rituximab: a case report.

Authors:  Shilpi Gupta; Anita Szerszen; Fadi Nakhl; Seema Varma; Aaron Gottesman; Frank Forte; Meekoo Dhar
Journal:  J Med Case Rep       Date:  2011-04-19

3.  Severe refractory autoimmune hemolytic anemia with five-year complete hematologic response to third course of treatment with rituximab: a case report.

Authors:  Kathleen Abadie; Kristen M Hege
Journal:  J Med Case Rep       Date:  2014-06-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.